secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001193125-23-045671
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal reports Q4 2022 cash $358.8M; positive Phase 3 NASH results support H1 2023 NDA filing
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $358.8M at Dec 31, 2022, up from $270.3M at Dec 31, 2021.
- Operating expenses $85.3M (Q4) and $293.6M (FY2022), vs $64.6M and $242.5M in prior year periods.
- R&D expenses $70.7M (Q4) and $245.4M (FY2022), increases due to Phase 3 trials and headcount.
- Positive Phase 3 MAESTRO-NASH results achieved both primary endpoints; NDA filing for resmetirom planned H1 2023.
- Secured $250M term loan facility with Hercules Capital and $300M+ in financing events in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000119312523045671/0001193125-23-045671-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000119312523045671/d449135d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-045671

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer